|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-7-26
|
|
pubmed:abstractText |
Vgamma9Vdelta2 (gammadelta) T lymphocytes, a critical peripheral blood lymphocyte subset, are directly cytotoxic against many solid and hematologic tumor types. Vgamma9Vdelta2 T lymphocytes can be selectively expanded in vivo with BrHPP (IPH1101) and IL-2. The present phase I trial was conducted with the aim of determining the maximum-tolerated dose (MTD) and safety of IPH1101 combined with a low dose of IL-2 in patients with solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1432-0851
|
|
pubmed:author |
pubmed-author:AudrainMarieM,
pubmed-author:BennounaJaafarJ,
pubmed-author:Bruzzoni-GiovanelliHeribertoH,
pubmed-author:CalvoFabienF,
pubmed-author:GaléaCélineC,
pubmed-author:HiretSandrineS,
pubmed-author:LevyVincentV,
pubmed-author:RimbertMarieM,
pubmed-author:RollandFrédéricF,
pubmed-author:SenellartHélèneH,
pubmed-author:SicardHélèneH,
pubmed-author:TiollierJéromeJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1521-30
|
|
pubmed:meshHeading |
pubmed-meshheading:20563721-Adult,
pubmed-meshheading:20563721-Aged,
pubmed-meshheading:20563721-Antineoplastic Agents,
pubmed-meshheading:20563721-Diphosphates,
pubmed-meshheading:20563721-Dose-Response Relationship, Drug,
pubmed-meshheading:20563721-Female,
pubmed-meshheading:20563721-Humans,
pubmed-meshheading:20563721-Interleukin-2,
pubmed-meshheading:20563721-Male,
pubmed-meshheading:20563721-Maximum Tolerated Dose,
pubmed-meshheading:20563721-Middle Aged,
pubmed-meshheading:20563721-Neoplasms,
pubmed-meshheading:20563721-T-Lymphocyte Subsets,
pubmed-meshheading:20563721-T-Lymphocytes
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors.
|
|
pubmed:affiliation |
Department of Medical Oncology, Centre René Gauducheau, 44805, Nantes-Saint-Herblain, France. j-bennouna@nantes.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase I
|
